

Attorney Docket No.: 3556.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Serial No.: 09/056,343

Group Art Unit: 1643

Filed: April 7, 1998

Examiner: William Moore

For: Proteins with Changed Epitopes and Methods for the Production Thereof

CERTIFICATE OF FACSIMILE TRANSMISSION

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED  
JUL 10 1998  
GROUP 1800

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. PTO-1449

was sent to the United States Patent Office by telefax to the attention of Examiner William Moore, fax number (703) 308-0294.

Respectfully submitted,

Date: July 9, 1998

Carol E. Rozek  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 3556.224-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Uffe Loevborg

Serial No.: 09/056,343

Group Art Unit: 1643

Filed: April 7, 1998

Examiner: William Moore

#3

For: Proteins with Changed Epitopes and Methods for the Production Thereof

INFORMATION DISCLOSURE STATEMENTHon. Commissioner of Patents and Trademarks  
Washington, DC 20231RECEIVED  
JUL 10 1998  
GROUP 1800

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references was filed in US application serial no. 08/346,590 filed November 29, 1994, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. U.S. Patent No. 3,903,068
2. Geysen et al., Science, Vol. 235, pp. 1184-90 (1987)
3. Geysen et al., J. Molec. Recog., Vol. 1, No. 1, pp. 32-41 (1988)
4. Walsh et al., J. Immun. Methods, Vol. 121, pp. 275-280 (1989)
5. Zachariae et al., Allergy, Vol. 36, pp. 513-516 (1981)

6. Arlian et al., Int. Arch Allergy Appl Immunol, Vol. 91, pp. 278-284 (1990)
7. Favre et al., Molecular Immunology, Vol. 26, No. 1, pp. 17-25 (1989)
8. Schlegel et al., The J. of Biological Chem., Vol. 259, No. 8, p. 4691-4694, 1984;
9. Chersi et al., Molecular Immunology, Vol. 21, No. 10, p. 847-852, 1984;
10. Westhof et al., Nature, Vol. 311, No. 13, 1984; and
11. Friguet et al., Molecular Immunology, Vol. 21, No. 7, p. 673-677, 1984.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: July 9, 1998

Carol E. Rozek  
Carol E. Rozek, Reg. No. 36,993  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123